
The Lung in AIDS

M. Mujahid Salim, M.D., Amatal B. Mir, M.B.
Stony Brook, New York

Abstract

AIDS has assumed epidemic proportions. The lungs are commonly involved and recurrent infections with opportunistic organisms occur. These are relatively refractory to eradication. Newer agents have had some limited success against these organisms. A vaccine is currently under trial.

Key words: *Acquired Immune Deficiency Syndrome, Human Immune Deficiency virus, pulmonary infections, new therapeutic agents.*

Introduction

The discovery of Acquired Immune Deficiency Syndrome (AIDS) in 1981 has attracted more publicity and generated more fear than any infectious disease in recent times. Over 30,000 cases have so far been reported to the Center for Disease Control (CDC); 56% of these have died. The total number of AIDS cases has increased each year, about 7,000 cases being reported in 1986 alone. The estimated cost for the first 9,000 cases was more than \$2.5 billion.

Epidemiology

The major risk groups include homosexual males (75%), intravenous drug abusers (20%), blood product recipients (2%, primarily hemophiliacs), infants and young children whose parents have AIDS and Haitian immigrants (3.6%). The retrovirus causing AIDS is not transmitted by casual association, but through intimate sexual contact, sharing contaminated needles, transfusion of whole blood, blood cellular components, plasma, or clotting factor concentrates, and from infected mother to child perinatally.¹

Etiology

In 1984 a retrovirus was identified as causing AIDS.² This contains a single stranded RNA genome

and a DNA synthesizing enzyme reverse transcriptase. It was named Human T cell leukemia virus, Type III (HTLV-III). Recently, this name was changed to Human Immunodeficiency Virus, HIV. This virus has been recovered from blood, saliva and semen of patients with AIDS. It infects and kills T-4 helper cells; lymphopenia, anergy and polyclonal elevation of serum immunoglobulins also occurs. HIV is also neurotropic, causing acute and chronic neurological diseases. Thus encephalopathy and dementia are often seen in AIDS patients.³

Serologic testing

An enzyme-linked immunosorbent assay, ELISA, to detect antibodies to HIV has been developed. It is 98.6% specific and 97.3% sensitive. The Western Blot method is more sensitive (100%), but less economical.⁴ Recently, monoclonal antibodies have been used to detect HIV antigens much earlier in the course of HIV infection.

Diagnosis

To make the diagnosis of AIDS, the CDC requires the presence of an unexplained opportunistic infection and/or unusual neoplasm in an individual with no recognized cause for such a susceptibility. Another diagnostic entity; AIDS Related Complex (ARC), occurs weeks to months prior to documented AIDS, and consists of nonspecific systemic symptoms (such as fever, fatigue, weight loss, wasting and diarrhea), generalized lymphadenopathy, localized opportunistic infections including oral candidiasis, and herpes zoster. Seropositivity for HIV antibody is found in 84% - 100% of these patients.

Clinical Manifestations of AIDS

Pneumocystis pneumonia remains the most common infection found in 47% of newly diagnosed

*From the Division of Pulmonary Medicine,
Department of Medicine, Queens Hospital Center
Affiliation of the Long Island Jewish Medical Center
State University of New York at Stony Brook, New York.*

Reprint requests: M. Mujahid Salim, M.D.
2726 Matlock Road, Suite C
Arlington, Texas 76014

cases and 63% of all cases of AIDS. Kaposi's sarcoma is found in 24%, Candidal esophagitis in 14%, cytomegalovirus in 75%, and all other infections have an occurrence of less than 5% of patients with AIDS. Multiple infections are usually present and are difficult to eradicate. Inflammatory responses, e.g., granuloma formation are often absent. Radiographic patterns are nonspecific and do not help to distinguish between the different pathogens.

I. Protozoan infections

Pneumocystis carinii pneumonia (PCP): Compared with PCP in other immunosuppressed patients, e.g. those with neoplastic disease, or on steroid therapy, the onset of PCP in AIDS patient is insidious and prolonged (weeks to months).⁵ Fever, dyspnea, and non-productive cough may occur, sometimes progressing to respiratory failure. Pathologically, the lungs reveal massive consolidation on gross examination. Histologically, the alveoli are filled with a proteinaceous foamy, eosinophilic material containing pneumocystis cysts and trophozoites. These cause an inflammatory response in the interstitium, though not invading the epithelium. *P. carinii* does not grow in culture media, but does take up methenamine-silver, toluidine blue-O, Gram and Giemsa stains and is also recognized by immunofluorescence. A chest roentgenogram often shows interstitial infiltrates and/or alveolar densities. It may, however, be clear initially. Arterial blood gases measurement show hypoxemia at rest or with exercise. A gallium scan shows a diffuse uptake while the diffusion capacity is decreased. Early bronchoscopy is preferred, and bronchoalveolar lavage has a high yield.⁶ The need for transbronchial specimens and open lung biopsy is thus reduced. PCP usually responds to treatment with trimethoprim/sulfamethoxazole (Bactrim, Septra) or pentamidine (Pentam 300) given for a minimum of two to three weeks.⁷ Hypersensitivity reactions to these agents are much more frequent in AIDS than in other patients. Skin rash or leukopenia may occur with trimethoprim/sulfamethoxazole;⁸ while hypotension, local pain, hypoglycemia, hyperglycemia, hypercalcemia, peripheral neuropathy, hepatic, renal and hematologic dysfunction may be seen with pentamidine. Alpha-difluoromethyl ornithine, DFMO, is an experimental agent showing promising results; reversible thrombocytopenia is one of its toxic effects. The combination of pyrimethamine and sulfadoxine (Fansidar) has been tried with initial success as a prophylactic drug.¹⁶ Stevens-Johnson syndrome may occur with this, especially in patients with skin hypersensitivity to Bactrim. Dapsone also has shown some effect on PCP.¹⁷

Finally, AZT (3'-azido-3'-deoxythymidine) appears promising in PCP treatment.⁹ It suppresses

replication of the retrovirus, though reports of bone marrow suppression due to AZT therapy have recently been reported. Other protozoan infections like cryptosporidiosis and toxoplasmosis may abound in AIDS victims, involving the gastrointestinal tract and central nervous system, respectively.

II. Bacterial infections

A. Mycobacterium Tuberculosis is not often seen as an opportunistic infection in AIDS patients from the U.S.A. but may present earlier in the pre-AIDS or ARC stages. Severe tuberculosis is, however, seen in the Haitian AIDS patients, often presenting as extrapulmonary and/or disseminated disease. Mediastinal lymphadenopathy, lower lobe and diffuse bilateral disease with absence of cavitation may occur.^{10,11} INH prophylaxis is suggested by some authors for Haitians with AIDS.

B. Mycobacterium avium intracellulare (MAI) causes a disseminated disease in patients with AIDS who present with fever, weight loss, abnormal liver function tests, and pancytopenia. In a study from Queens Hospital 3 out of 15 AIDS patients had MAI infection. Diagnosis is made on positive cultures from blood, lymph nodes, liver, spleen, or bone marrow specimens. MAI is the commonest bacteremia in AIDS. Positive sputum and bronchoscopic washings are considered by some to be adequate evidence of dissemination. Poor results have been obtained from treatment by conventional antituberculosis drugs and a combination of Ansamysin, Clofazimine and Ethionamide has been suggested.¹²

C. Other bacterial infections: AIDS is associated with an increased incidence of bacterial pneumonias, especially hemophilus influenzae and streptococcus pneumoniae.

III. Fungal infection

A. Candidiasis: Candidal infection of the oropharynx, esophagus, and rectum is the commonest infection in AIDS. Dissemination rarely occurs and may be associated with pulmonary involvement. Oral Nystatin, Ketoconazole or Amphotericin B may be used depending on the severity of the infection.

B. Cryptococcosis: The pulmonary infection this may induce is usually mild though the lung is usually the site of localization. The central nervous system is most frequently involved. Headaches, fever, nausea, vomiting, retinitis, lymphadenopathy and peritonitis may be present.¹² The presence of *C. neoformans*, antigens, and budding yeast in the cerebrospinal fluid clinches the diagnosis. Treatment with Amphotericin B plus 5-Fluorocytosine or high doses of Amphotericin B alone brings about a good initial

Table 1. Pulmonary Involvement in AIDS

Organism	Clinical Manifestations
I. Infections	
A. Protozoa	
i. <i>Pneumocystis carinii</i>	Pneumonia
ii. <i>Toxoplasma gondii</i>	Encephalitis, dissemination
B. Fungi	
i. <i>Cryptococcus neoformans</i>	Dissemination
ii. <i>Histoplasma capsulatum</i>	Dissemination
iii. <i>Aspergillus fumigatus</i>	Dissemination
iv. <i>Candida sp.</i> dissemination	Stomatitis, esophagitis,
v. <i>Mucor</i>	Dissemination
vi. <i>Coccidioides immitis</i>	Dissemination
vii. <i>Petrellidium Boydii</i>	Pneumonia
C. Viruses	
i. Cytomegalovirus	Retinochoroiditis, pneumonia dissemination
ii. Herpes simplex	Dissemination
iii. Herpes zoster-varicella	Dissemination
D. Bacteria	
i. <i>Mycobacterium avium-intracellulare</i>	Dissemination
ii. <i>Mycobacterium tuberculosis</i>	Dissemination
iii. <i>Hemophilus influenzae</i>	Pneumonia
iv. <i>Streptococcus pneumoniae</i>	Pneumonia
v. <i>Nocardia sp.</i>	Pneumonia
vi. <i>Mycobacterium Kansasii</i>	Pneumonia
vii. <i>Legionella spp.</i>	Pneumonia
II. Non-infectious	
A. Kaposi's sarcoma	Parenchymal infiltrate, lymphadenopathy, pleural effusions
B. Non-Hodgkin's lymphoma	Parenchymal infiltrate, lymphadenopathy, pleural effusions

response.¹⁴

C. Other Fungal Infections: Pulmonary infection with *Histoplasma capsulatum* and *Coccidioides immitis* has also been reported in AIDS patients.

IV. Viral infections

Cytomegalo virus: CMV invades the lung, infecting alveolar cells and macrophages leading to interalveolar edema and exudate production. Hyaline membranes may appear. Symptoms such as dyspnea, tachypnea, and chest pain may occur. The chest roentgenogram shows scattered pulmonary infiltrates while an arterial blood gas analysis shows hypoxemia. The disease may be mild, or progress to Adult Respiratory Distress Syndrome (ARDS). The diagnosis requires tissue or cytology material, usually from a lung biopsy, showing histologic evidence of typical intranuclear inclusion bodies. Dihydropropoxymethylguanine (DHPG) has been tried with some success. Interferon is also thought to be promising. Other viruses like Herpes simplex, Herpes zoster and Epstein-Barr virus are also known

to cause morbidity in AIDS patient.

V. Other infections

Infection with legionella, Group B Streptococcus, *Branchamella catarrhalis*, *Staphylococcus aureus*, *Nocardia* and *Aspergillus* have been described in AIDS patients. Bronchial presence of *Toxoplasma Gondii* and *Cryptosporidium* have also been reported.

VI. Non-infectious Pulmonary Disease

Kaposi's sarcoma is the most common malignancy involving the tracheobronchial tree and pleura, as well as the lung parenchyma in AIDS patients. The lack of desaturation with exercise and air flow obstruction, suggest tumor involvement rather than infection. The endobronchial appearance is characteristic, as reddish lesions are seen. The yield on biopsy is only 24 percent. The incidence of non-Hodgkins lymphoma has been on the increase too. The lungs are involved in a few of these cases.¹⁵ The different types of pulmonary involvement in AIDS patients and approaches to therapy are summarized in tables 1 and 2.

Diagnostic approach

Pulmonary involvement in AIDS is so varied that a differential diagnosis must be entertained. If bronchoscopy with a Broncho Alveolar Lavage (BAL) and transbronchial lung biopsy is non-diagnostic, an open lung biopsy may be considered. Empiric therapy maybe given according to clinical presentation. A schematic representation of the dragnostic approach is given in Figure 1.

Prevention

A vaccine is currently under trial and 'safe' sex is being promoted, but in spite of joint efforts on the part of many countries the disease continues to assume epidemic proportions. Over 1.5 million people, or about one in every thirty men between the ages of twenty and fifty may already carry the virus. Wide scale testing is thus being advised. A sum of \$75,000 is estimated per patient, for hospital and medical treatment costs, from diagnosis till death. It is time the public be made aware of the full impact of the disease, and laws be enacted to stem transmission of the virus without infringing upon civil liberties of the public.

Editor's Note. For the Islamic Perspective, refer to Noorwali, AA, Elawad AAR JIMA 1987; 19: 88-90.

Table 2: Therapy for AIDS-Related Pulmonary Infections

Phase	Nonspecific Treatment	Specific Treatment
Unconfirmed suspicion of AIDS-related pulmonary involvement	Aggressive support.* Diagnostic workup (BAL, bone marrow/lymph node/liver biopsy).	Empiric TMP-SMX,** IV, or pentamidine, IM/IV in sick patients. Empiric anti-TB therapy in high-risk patients (e.g. Haitians, TB contacts)
Established diagnosis	Aggressive support. Vigilance for additional infections	No empiric therapy for other infections TMP-SMX, IV, or pentamidine, IM/IV for PCP† (2-3 weeks). Anti-TB therapy (drug selection based on history) for TB. Amphotericin B, IV, for fungi and multidrug regimens for MAI ^a ††; experimental drugs for CMV ^a
Failure or unacceptable side effects	Repeated attempts to find additional infections	Switch drugs in PCP; experimental drugs if both failed. Add drugs in TB or mycoses
Improvement resolution	Close observation for relapse, recurrence, or new infections	Prophylaxis in PCP. Standard 9-month therapy in TB. Long-term continuation of therapy in mycoses.

^aExperimental treatment modalities of unproven value.


*Broncho - alveolar lavage

**Trimethoprim/Sulfamethoxazole

†Pneumocystis carinii pneumonia

††Mycobacterium avium intracellulare

Table 3. A Practical approach to Pulmonary Infections in AIDS



References

1. Jett JR, et al: Acquired immuno deficiency syndrome associated with blood-product transfusions. *Ann Intern Med* 1983; 99:621-24
2. Levy JA, et al: Isolation of lymphocytopathic retrovirus from San Francisco patients with AIDS. *Science* 1984; 225:840-42
3. Levy RM, Brudesen DE, and Rosenblum ML: Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience at UCSF and review of the literature. *J Neurosurg* 64:475
4. Weiss SH, et al: Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. *JAMA* 1985; 253:221-25
5. Kovacs JA, Masur H: Opportunistic infections in AIDS: Advances in host defense mechanisms. New York, Raven Press, 1985, vol 5, pp 35-58
6. Stover DE, et al: The usefulness of bronchoalveolar lavage in diagnosing infiltrates in the immunocompromised host. *Ann Intern Med* 1984; 76:101-17
7. Haverkos HW: Assessment of therapy for Pneumocystis carinii pneumonia. *Am J Med* 1984; 76:501-508
8. Gordin FM, Simon GL, Wofsy CB, and Mills J: Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired

- immunodeficiency syndrome. *Ann Intern Med* 1984; 100:495-99
9. Donath J, Khan FA: Pulmonary infections in AIDS. *Compr Ther* 1987; 13:49-58
 10. Pape JW, et al: Characteristics of the acquired immunodeficiency syndrome (AIDS) in Haiti. *N Engl J Med* 1983; 309:945-50
 11. Pitchenik AE, Rubinson HA; The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. *An Rev Respir Dis* 1985; 131:393-96
 12. Polsky B, Gold JWM, Whimberly E, et al: Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. *Ann Intern Med* 1986; 104:38-41
 13. Zuger A, Louie E, Holzman RS, et al: Cryptococcal disease in patients with the acquired immunodeficiency syndrome. *Ann Intern Med* 1986; 104:234-40
 14. Kovacs JA, Krovacs AA, Polis M, et al: Cryptococcosis in the acquired immunodeficiency syndrome. *Ann Intern Med* 1985; 103:533-38
 15. Safai B, and Koziner B: Malignant neoplasms in AIDS. In V.T. DeVita, S. Hellman, and S.A. Rosenberg (eds), *AIDS: Etiology, diagnosis, treatment, and prevention*. Philadelphia: J.B. Lippincott. 1984; pp 213-22.
 16. Gottlieb MS, Knight S, Mitsuyasu R, et al: Prophylaxis of pneumocystis carinii, pneumonia in AIDS with pyrimethamine—Sulfadoxine (Fansidar). *Lancet* 1984; 2:398-99
 17. Hughes WT, and Smith BC: Efficiency of Diaminodiphenylsulfone and other drugs in Murine *Pneumocystis Carinii* Pneumonitis. *Antimicrob Agents Chemo Ther* 1984; 26:436-40

